Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients

Solomayer, EF; Gebauer, Gerhard; Hirnle, P; Janni, Wolfgang; Lück, Hans-Joachim; Becker, Sven; Huober, Jens; Krämer, B.; Wackwitz, Birgit; Wallwiener, D.; Fehm, Tanja

doi:10.1093/annonc/mdr612

Cited by 64 publications

(39 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This contention is supported by preliminary clinical evidence showing that zoledronate in combination with standard anticancer therapy significantly reduces the prevalence of DTCs in the bone marrow from patients with early-stage breast cancer, when compared with standard therapy alone. 7,12 Further studies are however required to determine whether the reduction of DTCs by zoledronate provides clinical benefit.…”

Section: Preclinical and Clinical Translational Evidence Supporting Amentioning

confidence: 99%

Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities

Clézardin

2013

BoneKEy Reports

View full text Add to dashboard Cite

Section: Preclinical and Clinical Translational Evidence Supporting Amentioning

confidence: 99%

Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities

Clézardin

2013

BoneKEy Reports

View full text Add to dashboard Cite

“…Small trials have already demonstrated that dormant DTC in bone marrow of primary breast cancer patients can be eliminated by bisphosphonates. 59 …”

Section: Targeting the Microenvironmentmentioning

confidence: 99%

Dormancy in breast cancer

Banys

Hartkopf

Krawczyk

et al. 2012

BCTT

View full text Add to dashboard Cite

Tumor dormancy describes a prolonged quiescent state in which tumor cells are present, but disease progression is not yet clinically apparent. Breast cancer is especially known for long asymptomatic periods, up to 25 years, with no evidence of the disease, followed by a relapse. Factors that determine the cell's decision to enter a dormant state and that control its duration remain unclear. In recent years, considerable progress has been made in understanding how tumor cells circulating in the blood interact and extravasate into secondary sites and which factors might determine whether these cells survive, remain dormant, or become macrometastases. The mechanisms of tumor cell dormancy are still not clear. Two different hypotheses are currently discussed: tumor cells persist either by completely withdrawing from the cell cycle or by continuing to proliferate at a slow rate that is counterbalanced by cell death. Because dormant disseminated tumor cells may be the founders of metastasis, one hypothesis is that dormant tumor cells, or at least a fraction of them, share stem cell-like characteristics that may be responsible for their long half-lives and their suggested resistance to standard chemotherapy. Therefore, knowledge of the biology of tumor cell dormancy may be the basis from which to develop innovative targeted therapies to control or eliminate this tumor cell fraction. In this review, we discuss biological mechanisms and clinical implications of tumor dormancy in breast cancer patients.

show abstract

“…Also, its synergistic effect with chemotherapeutics has been recently studied in Ewing sarcoma [58]. Moreover, ZOL seems to reduce the persistence of DTCs in the bone marrow of patients with early breast cancer [59,60]; hence, some investigators have suggested that it could be used in adjuvant setting, in order to prevent bone metastases from solid tumors [61]. In preclinical studies it has been suggested that ZOL might be used as a potential anti-metastatic agent in different solid tumors, since it greatly affects tumor invasion capacity and dissemination [62].…”

Section: Bisphosphonatesmentioning

confidence: 99%

Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment

Criscitiello

Viale

Gelao

et al. 2015

Cancer Treatment Reviews

View full text Add to dashboard Cite

Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients

Cited by 64 publications

References 20 publications

Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities

Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities

Dormancy in breast cancer

Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment

Contact Info

Product

Resources

About